CRISPR-Cas in translational research: From molecular mechanisms to therapeutic applications in human disease (Review)
International Journal of Molecular Medicine · 20.11.2026 · 59 (1) · 1-31
DOI: 10.3892/ijmm.2026.6061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 20.11.2026. Verfasst von Muhammad Iqbal und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) systems are transformative tools in biomedical research, enabling precise and programmable manipulation of genetic material. Originally identified as adaptive immune mechanisms in bacteria and archaea, CRISPR-Cas technologies have evolved into versatile platforms for genome editing, disease modeling, molecular diagnostics and therapeutic development. Their simplicity, efficiency and adaptability have accelerated applications across a wide range of human diseases, including inherited genetic disorders, infectious disease, cancer and immune-mediated conditions. The present review provides a comprehensive overview of the molecular mechanisms, classification and evolution of CRISPR-Cas systems, with particular emphasis on their translational applications in modern medicine. The present review aimed to summarize advances in disease modeling, functional genomic screening, diagnostic platforms and therapeutic genome editing, as well as the clinical progress of CRISPR-based interventions, including ex vivo cell therapies and emerging in vivo gene editing approaches, while distinguishing their relative stages of clinical maturity. Beyond therapeutic opportunities, challenges continue to limit the widespread clinical implementation of CRISPR technologies. Key barriers include off-target genome modification, inefficient delivery to specific tissue, limitations in large-fragment genome editing, immunogenicity of bacterial-derived Cas proteins, manufacturing and scalability constraints and uncertainties regarding long-term safety. The present review aimed to summarize ethical and regulatory considerations associated with human genome editing. The present review highlighted both the promise and the remaining challenges of CRISPR-Cas systems. Continued progress in editing precision, delivery technology, safety assessment and regulatory governance will be essential for realizing the full clinical potential of genome editing therapies.
Zitieren
APA
Iqbal, M., Ali, A., Gu, Y., Chen, J., & Zhang, B. (2026). CRISPR-Cas in translational research: From molecular mechanisms to therapeutic applications in human disease (Review). International Journal of Molecular Medicine, 59(1), 1-31. https://doi.org/10.3892/ijmm.2026.6061
Vancouver
Iqbal M, Ali A, Gu Y, Chen J, Zhang B. CRISPR-Cas in translational research: From molecular mechanisms to therapeutic applications in human disease (Review). International Journal of Molecular Medicine. 2026;59(1):1-31. doi:10.3892/ijmm.2026.6061
BibTeX
@article{Iqbal2026,
author = {Iqbal, Muhammad and Ali, Awais and Gu, Yuchao and Chen, Jin and Zhang, Bingqiang},
title = {CRISPR-Cas in translational research: From molecular mechanisms to therapeutic applications in human disease (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {59},
number = {1},
pages = {1--31},
doi = {10.3892/ijmm.2026.6061}
}
EUVIMED